An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00746967
First received: March 31, 2008
Last updated: September 3, 2008
Last verified: September 2008
  Purpose

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.


Condition Intervention Phase
Sexual Dysfunctions, Psychological
Sexual Arousal Disorder
Drug: sildenafil
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety/toleration of oral sildenafil. [ Time Frame: Continuous ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The score for each of the individual questions 3,5 and 9 on the SQoL-F [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The total satisfaction score on the Inventory of Treatment Satisfaction (ITS-modified EDITS) [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The score for each of the individual questions 3,5,6 and 7 on the ITS-modified EDITS [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The Arousal-lubrication Domain from the SFQ. The score for this domain is the sum of scores from Questions 11 and 12 from the SFQ [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The Arousal-sensation Domain from the SFQ. The score for this domain is sum of scores from Questions 7,8,9 and 10 from the SFQ. [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The total Quality of Life score on the Sexual Quality of Life (SQoL-F) [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The Desire domain from the SFQ. Specifically, the sum of scores from questions 1,2,3,4,15 and 28 (frequency of pleasurable thoughts, wanted to be touched, wanted sex, initiated sex, had sex with penetration, looked forward to sex, respectively). [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • Question 16 from the SFQ at Weeks 14 and 26 (enjoyment of penetration and intercourse). [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The Orgasm domain from the SFQ. The score for this domain is the sum of scores from questions 24,25 and 26 (orgasm frequency, level of pleasure and ease in achieving, respectively). [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • The individual questions of the Orgasm domain. [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • SFQ Question 27 (confidence as sexual partner). [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • SFQ Question 29 (disappointment with response). [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]
  • Global Efficacy Question (SFQ Question 34, satisfaction with whole of sexual life) [ Time Frame: Week 14 and Week 26 ] [ Designated as safety issue: No ]

Enrollment: 267
Study Start Date: January 2003
Study Completion Date: February 2004
Arms Assigned Interventions
Arm 1 Drug: sildenafil
sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Included were subjects who completed Pfizer study A1481082 or A1481123 without a major protocol violation and with all treatment-related adverse events resolved prior to crossover into the open-label study.
  • For subjects receiving hormone replacement therapy and/or selective serotonin reuptake inhibitor treatment, dosage of these must be stable at the start of this extension study and remain stable throughout.
  • Subjects should continue to maintain a stable sexual relationship throughout the study.

Exclusion Criteria:

  • Excluded were subjects who experienced either treatment-related serious adverse events or significant treatment-related laboratory abnormalities in the previous study, and subjects who misused study medication and/or failed to adequately account for study medication in the previous study, or who were non-compliant with visits.
  • Also excluded were subjects who were currently prescribed and/or taking nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or aerosols).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00746967

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
United States, Alaska
Pfizer Investigational Site
Anchorage, Alaska, United States, 99502
Pfizer Investigational Site
Anchorage, Alaska, United States, 99508
United States, Arizona
Pfizer Investigational Site
Tucson, Arizona, United States, 85712
Pfizer Investigational Site
Tucson, Arizona, United States, 85719
United States, Arkansas
Pfizer Investigational Site
Jonesboro, Arkansas, United States, 72401
United States, California
Pfizer Investigational Site
Albany, California, United States, 94706
Pfizer Investigational Site
Berkeley, California, United States, 94705
Pfizer Investigational Site
Beverly Hills, California, United States, 90210
Pfizer Investigational Site
Beverly Hills, California, United States, 90212
Pfizer Investigational Site
Burbank, California, United States, 91506
Pfizer Investigational Site
Fair Oaks, California, United States, 95628
Pfizer Investigational Site
Hermosa Beach, California, United States, 90254
Pfizer Investigational Site
Oakland, California, United States, 94612
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Diego, California, United States, 92108
Pfizer Investigational Site
Santa Monica, California, United States, 90404
Pfizer Investigational Site
Torrance, California, United States, 90505
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80012
United States, Connecticut
Pfizer Investigational Site
Hamden, Connecticut, United States, 06518
Pfizer Investigational Site
New London, Connecticut, United States, 06320
Pfizer Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Pfizer Investigational Site
Aventura, Florida, United States, 33180
Pfizer Investigational Site
Brooksville, Florida, United States, 34614
Pfizer Investigational Site
Jensen Beach, Florida, United States, 34957
Pfizer Investigational Site
Miami, Florida, United States, 33186
Pfizer Investigational Site
New Port Richey, Florida, United States, 34652
Pfizer Investigational Site
Palm Harbor, Florida, United States, 34683
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33028
Pfizer Investigational Site
Plantation, Florida, United States, 33324
Pfizer Investigational Site
St Petersburg, Florida, United States, 33710
Pfizer Investigational Site
Stuart, Florida, United States, 34996
Pfizer Investigational Site
Stuart, Florida, United States, 34994
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33409
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
Pfizer Investigational Site
Marietta, Georgia, United States, 30060
Pfizer Investigational Site
Savannah, Georgia, United States, 31405
United States, Idaho
Pfizer Investigational Site
Boise, Idaho, United States, 83702
Pfizer Investigational Site
Boise, Idaho, United States, 83712
United States, Indiana
Pfizer Investigational Site
Evansville, Indiana, United States, 47714
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46825
Pfizer Investigational Site
Newburgh, Indiana, United States, 47630
United States, Kansas
Pfizer Investigational Site
Leawood, Kansas, United States, 66211
United States, Kentucky
Pfizer Investigational Site
Crestview Hills, Kentucky, United States, 41017
Pfizer Investigational Site
Florence, Kentucky, United States, 41042
United States, Louisiana
Pfizer Investigational Site
Metairie, Louisiana, United States, 70002
United States, Maryland
Pfizer Investigational Site
Greenbelt, Maryland, United States, 20770
United States, Michigan
Pfizer Investigational Site
Kalamazoo, Michigan, United States, 49009
Pfizer Investigational Site
Southfield, Michigan, United States, 48034
United States, Missouri
Pfizer Investigational Site
Creve Coeur, Missouri, United States, 63141
United States, Nevada
Pfizer Investigational Site
Henderson, Nevada, United States, 89014
Pfizer Investigational Site
North Las Vegas, Nevada, United States, 89030
United States, New Jersey
Pfizer Investigational Site
New Brunswick, New Jersey, United States, 08903
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10021
Pfizer Investigational Site
Poughkeepsie, New York, United States, 12601
Pfizer Investigational Site
Rochester, New York, United States, 14609
Pfizer Investigational Site
White Plains, New York, United States, 10603
United States, North Carolina
Pfizer Investigational Site
Winston Salem, North Carolina, United States, 27103
Pfizer Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Pfizer Investigational Site
Beachwood, Ohio, United States, 44122-5402
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45267-0559
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19106
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19148
Pfizer Investigational Site
Reading, Pennsylvania, United States, 19606
Pfizer Investigational Site
Reading, Pennsylvania, United States, 19607-1649
Pfizer Investigational Site
Temple, Pennsylvania, United States, 19560
Pfizer Investigational Site
West Reading, Pennsylvania, United States, 19611-1499
United States, Rhode Island
Pfizer Investigational Site
Providence, Rhode Island, United States, 02904
United States, South Carolina
Pfizer Investigational Site
Anderson, South Carolina, United States, 29621
United States, Tennessee
Pfizer Investigational Site
Memphis, Tennessee, United States, 38119
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78705
Pfizer Investigational Site
Austin, Texas, United States, 78758
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Houston, Texas, United States, 77024
United States, Utah
Pfizer Investigational Site
Sandy, Utah, United States, 84070
United States, Virginia
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22903
Pfizer Investigational Site
Richmond, Virginia, United States, 23294
United States, Washington
Pfizer Investigational Site
Renton, Washington, United States, 98055
Pfizer Investigational Site
Seattle, Washington, United States, 98115
Pfizer Investigational Site
Seattle, Washington, United States, 98105
United States, Wisconsin
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53209
United States, Wyoming
Pfizer Investigational Site
Cheyenne, Wyoming, United States, 82001
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00746967     History of Changes
Other Study ID Numbers: A1481133
Study First Received: March 31, 2008
Last Updated: September 3, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Disease
Sexual Dysfunctions, Psychological
Mental Disorders
Pathologic Processes
Sexual and Gender Disorders
Sildenafil
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on October 22, 2014